FDA-approved immune checkpoint inhibitors target specific proteins such as PD-1, PD-L1, and CTLA-4 and have shown efficacy in treating various cancers, including cervical, breast, colon, bladder, head, neck, lung, liver cancers, and Hodgkin lymphoma [143]. This evidence concerns the gene CD274 and cancer.